We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aptamer Group Plc | LSE:APTA | London | Ordinary Share | GB00BNRRP542 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.015 | 3.95% | 0.395 | 12,077,413 | 11:20:38 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.38 | 0.41 | 0.395 | 0.38 | 0.38 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 860k | -2.96M | -0.0015 | -2.60 | 7.3M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:21:29 | O | 10,000,000 | 0.38 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/7/2025 | 14:53 | UK RNS | Aptamer Group PLC Holding(s) in Company |
| 08/7/2025 | 07:00 | UK RNS | Aptamer Group PLC Posting of Circular and Notice of General Meeting |
| 04/7/2025 | 11:36 | ALNC |  IN BRIEF: Aptamer raises GBP2 million for Optimer commercialisation |
| 04/7/2025 | 09:11 | UKMARKETNEWS | Aptamer Group Secures £2 Million to Accelerate Optimer® Technology Rollout |
| 04/7/2025 | 07:00 | UK RNS | Aptamer Group PLC Placing to raise £2.0 million |
| 30/6/2025 | 07:00 | UK RNS | Aptamer Group PLC Liver fibrosis breakthrough with Optimer® platform |
| 25/6/2025 | 07:00 | UK RNS | Aptamer Group PLC Agreement with global life sciences leader |
| 30/5/2025 | 10:40 | ALNC | AIM WINNERS & LOSERS: hVIVO shares dive on contract cancellations |
| 30/5/2025 | 09:44 | ALNC | Aptamer cheers second product development deal with Unilever |
| 30/5/2025 | 07:00 | UK RNS | Aptamer Group PLC Unilever second Optimer development programme |
Aptamer (APTA) Share Charts1 Year Aptamer Chart |
|
1 Month Aptamer Chart |
Intraday Aptamer Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/7/2025 | 16:52 | ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ | 6,600 |
| 22/5/2025 | 09:27 | Removal pf significant roadblock to enable our shares climb | 1 |
| 20/5/2025 | 11:29 | My opinion for what its worth | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:15:00 | 0.38 | 10,000,000 | 38,000.00 | O |
| 15:21:30 | 0.40 | 740,224 | 2,990.50 | O |
| 15:15:06 | 0.38 | 300,000 | 1,147.98 | O |
| 14:50:05 | 0.40 | 29,467 | 119.05 | O |
| 14:40:32 | 0.40 | 112,378 | 454.01 | O |
| Top Posts |
|---|
Posted at 11/7/2025 09:20 by Aptamer Daily Update Aptamer Group Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 0.38p.Aptamer currently has 1,920,000,000 shares in issue. The market capitalisation of Aptamer is £7,488,000. Aptamer has a price to earnings ratio (PE ratio) of -2.60. This morning APTA shares opened at 0.38p |
Posted at 01/7/2025 07:52 by someuwin when the APTA share price was 0.41p. Share price targets to hit their recent options...free stock charts from uk.advfn.com ...These are the targets they've set themselves 6 month's ago to hit their significant options - one third at 1.4p, one third at 2.0p and final third at 2.5p. These are set multiples higher than the current share price but they clearly believe they will be achieved. Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This share option package forms part of our long-term incentive plan designed to reward staff and management for delivering significant value to the majority of our shareholders. The Group has set aggressive share price targets, which I am confident we can achieve given the calibre of customers we are dealing with and the progress we have made on a number of opportunities reported on recently, both commercially and scientifically. I am excited by the rapid progress the team are making; their focus and the quality of their work is paving the way for great things to come. Our platform technology is gaining increasing traction in the marketplace, and we are well positioned, with a skilful and knowledgeable team and our newly appointed Scientific Advisory board, to be able to take advantage of this." |
Posted at 30/6/2025 07:46 by johnveals when the APTA share price was 0.34p. APTA is building a business with enormous potential based upon sound science with applications in several fields whilst working with global companies.I am investing in the business, not the share price, but I do expect the share price to multibag over the coming years, just how many bags remains to be seen. |
Posted at 30/6/2025 07:06 by someuwin when the APTA share price was 0.34p. 30 June 2025Aptamer Group plc ("Aptamer", the "Company" or the "Group") Significant advance in liver fibrosis treatment with Optimer® platform Aptamer unveils novel biomarker for targeted liver fibrosis therapy Optimer® breakthrough targets liver scarring cells, positioning Aptamer in $20bn fibrosis market Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is advancing its portfolio through a dual strategy of developing proprietary licensable assets and providing fee-for-service work for global pharmaceutical partners. Among its proprietary development projects, the liver fibrosis program represents a key focus, leveraging the Company's innovative Optimer® platform to address critical unmet medical needs. Today, Aptamer announces a significant milestone in this programme, having successfully identified and validated a novel molecular target for its proprietary Optimer® delivery platform, advancing its potential to deliver targeted gene therapy to the specific liver cells which drive scarring. This breakthrough enhances the commercial attractiveness of the platform, positioning Aptamer for strategic licensing discussions with global pharmaceutical partners. Liver scarring, known as fibrosis, affects millions worldwide and can progress to severe conditions like cirrhosis, liver failure, and cancer, with no current treatments able to reverse the damage. This condition is caused by specific liver cells, called hepatic stellate cells (HSCs), which create harmful scar tissue. With an estimated global market for fibrosis treatments exceeding $20 billion by 2030, based on industry projections, Aptamer's Optimer® platform addresses a critical unmet need. The Optimer® acts like a 'magic bullet', targeting a protein in scarred livers to deliver a gene therapy medicine, called siRNA, directly to HSCs. This siRNA switches off signals that drive scarring, offering a potential new way to reduce or reverse the condition. Aptamer used cutting-edge scientific methods, including genetic analysis, protein interaction studies, and cell imaging, to confirm that the Optimer® targets this protein with high precision. In laboratory tests mimicking liver damage, the Optimer®-siRNA system significantly reduced processes that mimic scar tissue formation and slowed the harmful activity of HSCs, such as excessive growth and movement that worsen scarring. These results demonstrate the platform's potential to transform liver fibrosis treatment by delivering gene therapy specifically to the cells causing the disease. The Optimer® was developed using Aptamer's innovative approach, which identifies targets unique to diseased cells, unlike traditional methods that may overlook key disease markers. This method uncovered a specific protein marker that enables precise targeting of HSCs, setting Aptamer's technology apart as a powerful tool for precision medicine. The Optimer® platform's compatibility with various RNA-based medicines makes it highly versatile, supporting partnerships across liver fibrosis and other scarring-related conditions. Aptamer is now working towards a series of outsourced in vivo studies to evaluate the Optimer® platform's performance in animal models, while engaging in ongoing discussions with major pharmaceutical companies to conduct parallel studies. These efforts aim to confirm the platform's efficacy and safety, paving the way for human trials and strategic collaborations. Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This milestone marks a major step forward in our mission to develop new treatments for liver fibrosis. By identifying a novel target for delivering gene therapy to the cells causing liver scarring, Aptamer has strengthened the Optimer® platform's value for our pharmaceutical partners. The laboratory results showing reduced scarring highlight the potential of this approach, and our plans for outsourced animal studies, alongside ongoing talks with big pharma, position us to accelerate development. This success underscores Aptamer's leadership in targeted drug delivery, opening doors to a significant market opportunity. "The Optimer® platform showed high selectivity for scarred liver tissue in lab tests, with no unwanted effects on healthy cells, and is designed to work with a range of RNA therapeutics, enhancing its commercial potential. This milestone positions Aptamer to capitalise on the growing demand for precision therapies in the multi-billion-dollar fibrosis market." |
Posted at 25/6/2025 07:04 by someuwin 25 June 2025Aptamer Group plc ("Aptamer", the "Company" or the "Group") Development and licensing agreement with global life sciences leader Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce a new development and licensing agreement with an established global company in the life sciences and diagnostics sector, part of a major multinational conglomerate (the "Partner"). Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC) assays and diagnostic kits, leveraging its proprietary Optimer®-Fc platform, which produces aptamer binders with an antibody Fc-tag optimised for IHC workflows. The Partner will fully fund the development work, which is expected to be completed within a 12-month timeline, for an undisclosed sum. Subject to development and validation, the Optimer®-Fc reagent is anticipated to be incorporated into commercial IHC kits, with a product launch expected within the current calendar year. The agreement includes a commercial licensing arrangement, under which Aptamer will receive royalties of 2% on net sales of all assay kits containing the licensed Optimer®-Fc reagent, subject to standard minimum royalty commitments. The kits are expected to be distributed through recognised global channels specialising in life sciences research products. This partnership strengthens Aptamer's recurring revenue potential and supports its strategy to expand the application of its Optimer platform in high-value life sciences markets. The collaboration with a globally respected industry leader underscores the commercial potential and technical capabilities of Aptamer's Optimer®-Fc technology for advanced diagnostic applications. Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are pleased to collaborate with a leading global life sciences company to develop this Optimer®-Fc reagent for IHC applications. The royalty structure and fully funded development provide a clear path to revenue generation and validate the strength of our Optimer platform. This agreement enhances our portfolio of royalty-generating assets and supports our mission to deliver innovative solutions to the life sciences industry." Certain details of the agreement, including specific financial terms and the identity of the Partner, are commercially sensitive and have not been disclosed at this stage. The Company will provide updates on material developments as appropriate. |
Posted at 30/5/2025 07:11 by someuwin ("Aptamer", the "Company" or the "Group")Unilever initiates second Optimer development programme Aptamer to receive undisclosed six-figure sum for second development in personal care Second programme expands Optimer applications following the success of the initial programme to date Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces the signing of a second Optimer discovery and development programme with global consumer goods leader, Unilever. Under the new agreement, Aptamer will develop a novel panel of Optimer binders targeting an additional biological pathway associated with body odour formation, potentially providing Unilever with a second strategy to prevent the formation of body malodour. The agreement is structured on a fee-for-service basis, with Aptamer receiving an undisclosed six-figure sum for the development work. This new programme builds on the success of the initial programme, which focused on inhibiting a key bacterial enzyme involved in body odour production. Optimers from the initial programme have passed internal validation and lab-based testing, both at Aptamer and Unilever, with on-person performance trials anticipated in 2025. Unilever commands over 30 per cent of the global deodorant market, compared to 10 per cent for its nearest competitor. With the sector expected to grow at a CAGR of 4.5 per cent over the next five years, the commercial opportunity for Aptamer in personal care is significant. This collaboration highlights the scalability and cross-sector potential of the Optimer platform, traditionally applied in therapeutic and diagnostic markets, and now entering the high-volume consumer health space. Dr Arron Tolley, Chief Executive Officer, Aptamer Group, said: "I am excited by the additional project we are undertaking with Unilever. This project expands our partnership with Unilever in the odour control space. The excellent results produced by our team in the first project have resulted in a deepening partnership with Unilever, expanding on the applicability of our Optimer binders. "The first project is now moving toward on-person trials, and this deal positions us well to create multiple, licensable assets with a global powerhouse in the consumer health market. This second programme reflects the confidence Unilever has in the Optimer platform and the significant value we can unlock by expanding our offering into novel, large-scale applications like personal care." Dr Sam Samaras, Senior Vice President R&D, Unilever, said: "This new project with Aptamer Group reflects the positive nature of the collaboration thus far. This was the first time that Unilever has examined Optimer binders in cosmetic applications and the data so far have shown encouraging results. We have agreed on a follow up project targeting novel approaches for odour control using Optimer technology. We will continue to engage with the world class team at Aptamer Group to explore this and additional opportunities." |
Posted at 19/5/2025 18:59 by strides1 As a layman, as I see it, the Aptamer-Group designs its unique treatments for precision targeting....The obvious application is for delivering the cancer treatment directly to the rogue cell and disarming it without damaging/poisoning adjacent/integral healthy cells....So plenty of scope for their development both for vetinary and human treatments, especiallyas they are non biological. So as non biological....they will not fall in the ethically unsuitable treatments trap...."ala Reneurons stem cell/ exesome harvesting" Moving on....the scope of applications is pretty well infinite....so I'm sure Aptamer will prioritise its applications/designs to maximise it commercial and ethical potential...As a layman....even I can see Aptamers potential is huge....they must surely be in the cross/wires of its several mega peers.... Consequently, I'm accumulating at these current silly low share prices....whilst frustrated by 'purchaseathetop' non-existent future funding fears... however they cannot stopc 'PAT ala DoubtingThomas' from airing their groundless fears.....if asked, my recommendation would be to ignore PAT and accumulate whilst these fears subside via education and example. |
Posted at 06/5/2025 07:12 by someuwin Aptamer Group plc("Aptamer", the "Company" or the "Group") Alzheimer's test advanced and royalty agreement Optimer-based test converted to common hospital format New test format enhances commercialisation potential Neuro-Bio agreement includes an 11.1% blended royalty rate on sales of clinical diagnostics Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce the successful adaptation of the Optimer-based test for Alzheimer's disease into an Enzyme-Linked Immunosorbent Assay (ELISA), a format widely accepted and used in hospital laboratories. Aptamer has also finalised a royalty agreement with its development partner, Neuro-Bio Ltd. Under the agreed terms, Aptamer is eligible to receive royalty payments with a blended royalty rate of 11.1% on the first £166 million of sales, with 5% thereafter for a 15-year term starting at first commercial sales across this diagnostic format. The partners estimate developing and validating a prototype ELISA assay over the next 12-18 months for transfer to a manufacturer or distributor. This advance in test development follows the recent demonstration of an Optimer-based biosensor test that showed a statistically significant difference in levels of a novel Alzheimer's disease biomarker between saliva samples from Alzheimer's patients and healthy patient controls. Initial in-house validation of the plate-based ELISA assay at Aptamer has shown accurate detection of the biomarker over a clinically relevant range and compatibility with saliva for convenient patient sampling. Further development efforts are being made to clinically validate the new test format. To capitalise on the potential of this patient-friendly test for Alzheimer's disease that uses saliva sampling, a staged diagnostic development strategy is now underway with Neuro-Bio, which aims to maximise market access with an initial focus on advancing the ELISA assay for widespread clinical adoption. The Alzheimer's disease diagnostic market is valued at $8.3 billion, limited by the availability of any definitive diagnostic tests, and is expected to rise to $19.6 billion by 2029.1 While several Alzheimer's diagnostics are in development, the test being developed by Aptamer and Neuro-Bio leverages non-invasive saliva sampling, offering a rapid, convenient and patient-friendly approach with the potential to transform the diagnostic market for this disease by increasing accessibility and accelerating time-to-diagnosis. Dr. Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "I am delighted that we have secured commercial terms with Neuro-Bio. This agreement underscores Apatmer's model to establish ongoing revenue-generating opportunities in high-growth markets from the Group's developed Optimer binders across its asset portfolio. Adapting the Optimer-based Alzheimer's diagnostic into a widely compatible test format is a significant step forward in the Group's mission to bring this test to market. The ability to integrate the test into existing hospital systems makes it easier for hospitals to adopt, providing a faster and easier route to market. The new strategic partnership with Neuro-Bio builds on the unique technical expertise of both companies to advance this innovative diagnostic solution toward commercialisation." Baroness Susan Greenfield, Chief Executive Officer of Neuro-Bio, commented: "We are very excited at the progress made by the collaboration between our two companies. The technical, innovative talent at Aptamer, when combined with our insights and unique approach to Alzheimer's disease, holds the promise of a real breakthrough for a major, currently unmet, clinical need. Our team has greatly enjoyed working with the Aptamer researchers and looks forward to an ever-closer relationship going forward." 1. Grand View Research. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), By Type (Triage, Diagnosis, Screening), By End-use, By Region, And Segment Forecasts, 2025 - 2030. Report ID: GVR-4-68040-323-7. - Ends - |
Posted at 10/2/2025 09:02 by gepetto100 Let's just be very clear about how committed the BoD are in relation to APTA. It will be highly successful- read onVirtually all of the Directors acquired stock post the placing mainly in December 24. A definite pointer to confidence in the current operations and contracts coming to fruition in 2025 This was also done on the back of a very effective cost cutting exercise and restructuring and the setting up of a Scientific Advisory Board (SAB) RNS dated 6th December who will review and advise on product strategies, scientific approaches, and evidence generation for data to enable clinical advancement.They will primarily be focused on addressing the commercialisation of the Group's internal development programmes for targeted delivery vehicles with diverse payloads.This Board are highly qualified industry experts: Dr Adam Hargreaves, Managing Director of Pathcelerate and Aptamer Chair Dr Paloma Giangrande, former CTO at Eleven Therapeutics and Editor-in-Chief at Molecular Therapy Nucleic Acids Dr Louis Allot, Radiochemistry Consultant at Radiopharmium Professor Paul Townsend, Deputy Principal of Research and Innovation at the University of Stirling Dr Shozo Fujita, Former Chief Technology Officer at Apta-BioAnd just to be clear about their qualifications Dr Paloma Giangrande is an internationally recognised expert in the development and translation of nucleic acid therapeutics and aptamer-based delivery. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver, significantly expanding the therapeutic potential of RNA interference. Paloma has held key leadership roles in renowned biotechnology companies, including Moderna, Wave Life Sciences, and Eleven Therapeutics. Her strategic leadership at prestigious institutions underscores her commitment to advancing innovative RNA-based treatments. Dr Louis Allot is an expert in the clinical development of radiopharmaceuticals |
Posted at 28/1/2025 08:07 by multibagger Good morning all !Another excellent update of progress commercially and scientifically ! A licensing deal in the fullness of time will be just the ticket to propel the APTA share price into orbit which could put the Trellus share price rise into the shade. Market will have to take notice of the building of momentum and fantastic progress being made ! Good luck all :) |
Posted at 29/12/2024 08:03 by roughandtumbleone Kingston.I've got my target set much higher based on two elements:- One being the incentivised options for the staff and Management of the company starting at 1.4pps and moving up to almost 3pps for the final tranche of options (see below)Secondly, with the collaboration with two significant pharmas I see a real opportunity for a mouthwatering deal with a chunky upfront payment and a decent licensing deal that could easily dwarf the current MC for annual royalties. (i) One third, on the share price having remained at or above 7 times the issue price for at least 3 months and exercisable 6 months following vesting;(ii) One third, on the share price having remained at or above 10 times the issue price for at least 3 months and exercisable 12 months following vesting;(iii) One third, on the share price having remained at or above 12.5 times the issue price for at least 3 months and exercisable 24 months following vesting; |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
